Der Nervenarzt

, Volume 79, Issue 2, pp 218–224

Entwicklungen neuer Therapiemöglichkeiten des Schlaganfalls

Perspektiven für Neuroprotektiva?
Aktuelles
  • 101 Downloads

Zusammenfassung

Schlaganfälle gehören zu den häufigsten Erkrankungen dieser Zeit. Die zahlreichen negativen klinischen Studien mit neuroprotektiven Substanzen führten zur Einführung von Empfehlungen der Stroke Therapy Academic Industry Roundtable (STAIR) für die präklinische und klinische Entwicklungsphase. Als Folge dieser verbesserten neuen Entwicklungen zeigte die erstmalig positive klinische Studie mit dem Radikalfänger NXY-059 ein ermutigendes Ergebnis (SAINT I), das sich allerdings in einer Folgestudie (SAINT II) nicht bestätigen ließ. In diesem Artikel analysieren wir kritisch die präklinische und klinische Entwicklung von Neuroprotektiva für die Schlaganfallbehandlung am Beispiel von NXY-059 und geben Empfehlungen für die mögliche zukünftige Entwicklung neuroprotektiver Substanzen.

Schlüsselwörter

Schlaganfall Neuroprotektion Klinische Studien NXY-059 

Development of new stroke therapies

Outlook for neuroprotective drugs

Summary

Stroke remains one of the most urgent medical problems of our times. The failure of most neuroprotective drugs in clinical trials led to the initiation of the Stroke Therapy Academic Industry Roundtable guidelines. Due to this improvement, the positive clinical trial results with the free radical scavenger NXY-059 (SAINT I) was encouraging. However, the subsequent SAINT II trial did not confirm these results. In this article we critically review the history of preclinical and clinical trials based on experience of NXY-059 development and present recommendations for potential future preclinical and clinical development of neuroprotective stroke therapy.

Keywords

Stroke Neuroprotection Clinical trials NXY-059 

Literatur

  1. 1.
    Stroke Therapy Academic Industry Roundtable (STAIR) (1999) Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30: 2752–2758Google Scholar
  2. 2.
    Bath PM, Sprigg N (2007) Colony stimulating factors (including erythropoietin, granulocyte colony stimulating factor and analogues) for stroke. Cochrane Database Syst Rev: CD005207Google Scholar
  3. 3.
    Ehrenreich H, Hasselblatt M, Dembowski C et al. (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8: 495–505PubMedGoogle Scholar
  4. 4.
    Fisher M, Hanley DF, Howard G et al. (2007) Recommendations from the STAIR V meeting on acute stroke trials, technology and outcomes. Stroke 38: 245–248PubMedCrossRefGoogle Scholar
  5. 5.
    Fisher M, Schabitz WR (2000) An overview of acute stroke therapy: past, present, and future. Arch Intern Med 160: 3196–3206PubMedCrossRefGoogle Scholar
  6. 6.
    Hacke W, Albers G, Al Rawi Y et al. (2005) The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36: 66–73PubMedCrossRefGoogle Scholar
  7. 7.
    Hacke W, Kaste M, Fieschi C et al. (1995) Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 274: 1017–1025PubMedCrossRefGoogle Scholar
  8. 8.
    Schroeder N (2007) Topline-Ergebnisse der DIAS-2-Studie zeigen keinen Unterschied zwischen Desmoteplase und Plazebo. Online Pressemitteilung vom 31.05.2007 http://www.paion.de
  9. 9.
    Kohrmann M, Juttler E, Fiebach JB et al. (2006) MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort study. Lancet Neurol 5: 661–667PubMedCrossRefGoogle Scholar
  10. 10.
    Kuroda S, Tsuchidate R, Smith ML et al. (1999) Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 19: 778–787PubMedCrossRefGoogle Scholar
  11. 11.
    Lapchak PA, Araujo DM, Song D et al. (2002) Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke 33: 1411–1415PubMedCrossRefGoogle Scholar
  12. 12.
    Lees KR, Davalos A, Davis SM et al. (2006) Additional outcomes and subgroup analyses of NXY-059 for acute ischemic stroke in the SAINT I trial. Stroke 37: 2970–2978PubMedCrossRefGoogle Scholar
  13. 13.
    Lees KR, Zivin JA, Ashwood T et al. (2006) NXY-059 for acute ischemic stroke. N Engl J Med 354: 588–600PubMedCrossRefGoogle Scholar
  14. 14.
    Marshall JW, Cummings RM, Bowes LJ et al. (2003) Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke 34: 2228–2233PubMedCrossRefGoogle Scholar
  15. 15.
    Marshall JW, Duffin KJ, Green AR, Ridley RM (2001) NXY-059, a free radical–trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke 32: 190–198PubMedGoogle Scholar
  16. 16.
    Ren JM, Finklestein SP (2005) Growth factor treatment of stroke. Curr Drug Targets CNS Neurol Disord 4: 121–125PubMedCrossRefGoogle Scholar
  17. 17.
    Rogalewski A, Schneider A, Ringelstein EB, Schabitz WR (2006) Toward a multimodal neuroprotective treatment of stroke. Stroke 37: 1129–1136PubMedCrossRefGoogle Scholar
  18. 18.
    Rothwell PM, Coull AJ, Silver LE et al. (2005) Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 366: 1773–1783PubMedCrossRefGoogle Scholar
  19. 19.
    Saver JL (2007) Clinical impact of NXY-059 demonstrated in the SAINT I trial: derivation of number needed to treat for benefit over entire range of functional disability. Stroke 38: 1515–1518PubMedCrossRefGoogle Scholar
  20. 20.
    Savitz SI (2007) A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp Neurol 205: 20–25PubMedCrossRefGoogle Scholar
  21. 21.
    Schabitz WR, Fisher M (2006) Perspectives on neuroprotective stroke therapy. Biochem Soc Trans 34: 1271–1276PubMedCrossRefGoogle Scholar
  22. 22.
    Schabitz WR, Kollmar R, Schwaninger M et al. (2003) Neuroprotective effect of granulocyte colony-stimulating factor after focal cerebral ischemia. Stroke 34: 745–751PubMedCrossRefGoogle Scholar
  23. 23.
    Schabitz WR, Schneider A (2007) New targets for established proteins: exploring G-CSF for the treatment of stroke. Trends Pharmacol Sci 28: 157–161PubMedCrossRefGoogle Scholar
  24. 24.
    Schneider A, Kruger C, Steigleder T et al. (2005) The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest 115: 2083–2098PubMedCrossRefGoogle Scholar
  25. 25.
    Schneider A, Kuhn HG, Schabitz WR (2005) A role for G-CSF (granulocyte-colony stimulating factor) in the central nervous system. Cell Cycle 4: 1753–1757PubMedGoogle Scholar
  26. 26.
    Shuaib A, Lees KR, Lyden P et al. (2007) NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 357: 562–571PubMedCrossRefGoogle Scholar
  27. 27.
    Sydserff SG, Borelli AR, Green AR, Cross AJ (2002) Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br J Pharmacol 135: 103–112PubMedCrossRefGoogle Scholar
  28. 28.
    Wahlgren NG, Ahmed N (2004) Neuroprotection in cerebral ischaemia: facts and fancies–the need for new approaches. Cerebrovasc Dis [Suppl 1] 17: 153–166Google Scholar
  29. 29.
    Yoshimoto T, Kanakaraj P, Ying MJ et al. (2002) NXY-059 maintains Akt activation and inhibits release of cytochrome C after focal cerebral ischemia. Brain Res 947: 191–198PubMedCrossRefGoogle Scholar
  30. 30.
    Yoshimoto T, Kristian T, Hu B et al. (2002) Effect of NXY-059 on secondary mitochondrial dysfunction after transient focal ischemia; comparison with cyclosporin A. Brain Res 932: 99–109PubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2008

Authors and Affiliations

  1. 1.Klinik und Poliklinik für NeurologieUniversitätsklinikumMünsterDeutschland

Personalised recommendations